Neurocrine, Mitsubishi Tanabe to develop VMAT2 inhibitor NBI-98854 for movement disorders
US-based Neurocrine Biosciences has entered into an exclusive collaboration and licensing agreement with Japanese firm Mitsubishi Tanabe Pharma to develop and commercialize its VMAT2...
Canada’s Valeant buys Salix for $11bn
Canada-based Valeant Pharmaceuticals International has completed the acquisition of US-based Salix Pharmaceuticals for around $11bn. Under the deal, Valeant has acquired all outstanding...
Perrigo completes acquisition of OTC drugmaker Omega Pharma for $4.5bn
Ireland-based Perrigo has completed the acquisition of Belgium's over-the-counter (OTC) drugmaker Omega Pharma for around €3.8bn ($4.5bn). As part of the deal, Perrigo...
BioCryst gets $35m contract for new Ebola treatment
BioCryst Pharmaceuticals has received a $35m contract to continue developing BCX4430, a drug that has shown early signs of fighting the Ebola virus. ...
Ireland’s Horizon Pharma to buy Hyperion for $1.1bn
Irish biopharmaceutical firm Horizon Pharma has signed an agreement to acquire US-based Hyperion Therapeutics for around $1.1bn. As part of the deal, Horizon...
CHMP recommends new single-pill combination therapy to treat type 2 diabetes
30 March 2015 The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Boehringer Ingelheim (BI) and Eli...
GSK to provide meningitis B vaccine in UK
GlaxoSmithKline (GSK) has entered an agreement with the UK's Department of Health to provide meningitis B vaccine for babies in the country. Meningitis...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...